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ARTICLE

Acute Myeloid Leukemia

RXRA DT448/9PP generates a dominant
active variant capable of inducing maturation
in acute myeloid leukemia cells
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ABSTRACT

R

ARA and RXRA contribute to myeloid maturation in both mice
and humans, and deletion of Rxra and Rxrb augments leukemic
growth in mice. While defining the domains of RXRA that are
required for anti-leukemic effects in murine KMT2A-MLLT3 leukemia
cells, we unexpectedly identified RXRA DT448/9PP as a constitutively
active variant capable of inducing maturation and loss of their proliferative phenotype. RXRA DT448/9PP was associated with ligand-independent activity in reporter assays, with enhanced co-activator interactions,
reduced engraftment in vivo, and activation of myeloid maturation transcriptional signatures that overlapped with those of cells treated with the
potent RXRA agonist bexarotene, suggestive of constitutive activity that
leads to leukemic maturation. Phenotypes of RXRA DT448/9PP appear
to differ from those of two other RXRA mutations with forms of constitutive activity (F318A and S427F), in that DT448/9PP activity was resistant to mutations at critical ligand-interacting amino acids
(R316A/L326A) and was resistant to pharmacological antagonists, suggesting it may be ligand-independent. These data provide further evidence that activated retinoid X receptors can regulate myeloid maturation and provide a novel constitutively active variant that may be germane for broader studies of retinoid X receptors in other settings.

Correspondence:

Introduction

JOHN S. WELCH
jwelch@wustl.edu

Retinoid receptors are highly conserved transcription factors that direct hematopoietic self-renewal and differentiation.1,2 Retinoids (vitamin A metabolites) bind directly
to retinoid receptors, converting the receptors from transcriptional repressors to transcriptional activators. There are six types of retinoid receptor (RARA, RARB, RARG,
RXRA, RXRB, RXRG) with distinct tissue expression and subtle differences in their
binding and response to different ligands. The retinoid receptors RARA and RXRA
undergo remarkable upregulation during myeloid maturation in both mice and
humans, whereas RXRG is not detected.3-5
Retinoid treatments, both in vitro and in vivo, facilitate hematopoietic stem cell maturation and lineage commitment.1,2 Until now, the clinical application of retinoids in
hematology has been restricted to acute promyelocytic leukemia (treated with all-trans
retinoic acid, or tretinoin, a pan-RAR ligand) and cutaneous T-cell leukemia (treated
with bexarotene, a pan-RXR ligand). However, recent studies have observed activity
of all-trans retinoic acid when combined with chemotherapy in acute myeloid
leukemias other than the promyelocytic form, and the RARA super-enhancer has
emerged as a potential biomarker of retinoid sensitivity.6-10
To better understand the molecular determinants of anti-leukemic retinoid activity,
we evaluated a series of RXRA truncations and mutations to determine which might
rescue phenotypes observed in Rxra/Rxrb-deficient leukemia cells.5 We unexpectedly
identified RXRA DT448/9PP as a constitutively active variant capable of inducing maturation and loss of proliferative capacity in leukemia cells. In this study, we characterized the activity of this variant using cell culture assays, transcription reporter assays,
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in vivo engraftment, and RNA sequencing, and present evidence of ligand-independent loss of proliferative capacity,
transcriptional signatures of myeloid maturation that overlap with signatures induced by the potent RXR ligand
bexarotene, and inhibition of engraftment and leukemic
expansion in vivo. These data again suggest that programs of
leukemic cell growth and maturation may be susceptible to
retinoids and provide a novel constitutively active tool for
further delineating the function and activity of retinoid
receptors.

package edgeR was used to determine genes that were differentially expressed between groups: RXRA WT cells, RXRA WT cells
treated with bexarotene , and RXRA DT448/9PP-transduced cells.
Differentially expressed genes were defined as having an absolute
log fold change >2 and a P-value <0.0001. Functional pathway
analysis was performed using Panther Gene Ontology Analysis
software14 with a Fisher exact test using the Bonferroni correction
for multiple testing. Pathways were called if P<0.05 and fold
enrichment was >2. Gene set enrichment analysis was performed
using gene sets curated in the MSigDB database and GSEA 4.0.3
software; RRID:SCR_003199.15

Methods

Study approval

Mice

All animal procedures were approved by the Institutional
Animal Care and Use Committee of Washington University.

Mice were maintained in a specific pathogen-free barrier facility
with a 12 h light-dark cycle. Upon weaning, all mice were housed
in groups of up to five mice of the same sex per cage. Food and a
water bottle were provided in a recess of the metal wire lid at the
top of the cage. Cages were changed once every week. Six- to tenweek-old mice (C57Bl/6 background) were typically used for the
experiments. Equal numbers of male and female mice were used;
no gender biases were noted.

Hematopoietic cell culture
Murine bone marrow Kit+ cells were isolated using an
Automacs Pro (Miltenyl Biotec, San Diego, CA, USA) according to
the manufacturer’s protocol. Kit+ cells were plated in progenitor
expansion medium (RPMI 1640 medium, 15% fetal bovine serum,
stem factor [50 ng/mL], interleukin 3 [10 ng/mL], Flt3L [25 ng/mL],
thrombopoietin [10 ng/mL], L-glutamine [2 mM], sodium pyruvate [1 mM], HEPES buffer [10 mM], penicillin/streptomycin [100
units/mL], b-mercaptoethanol [50 mM]) overnight and transduced
with MSCV-KMT2A-MLLT3 retrovirus by spinfection with 10
µg/mL polybrene and 10 mM HEPES at 2400 rpm, 30°C for 90 min
in an Eppendorf 5810R centrifuge. Cells were transplanted into
sublethally irradiated mice and subsequent leukemia harvested 4
to 6 months later. KMT2A-MLLT3 leukemia cells were cultured in
vitro using similar media, but without Flt3L or thrombopoietin.
KMT2A-MLLT3-RXR-knockout (KO) leukemia cells were derived
from Mx1-Cre x Rxraflox/flox x Rxrbflox/flox bone marrow cells11,12 transduced with MSCV-KMT2A-MLLT3 retrovirus and generated as
described above. RXR deletion was induced by injecting Mx1-Cre
x Rxraflox/flox x Rxrbflox/flox mice intraperitoneally with pIpC 300
mg/mouse; four doses were given, every other day. RXR deletion
was confirmed by polymerase chain reaction analysis 4 weeks
after mice had been treated with pIpC. THP1, and K562 cells were
obtained from the American Type Culture Collection. Monomac6 and OCI-AML3 cells were obtained from the Deutsche
Sammlung von Mikroorganismen und Zellkulturen.

RNA sequencing
KMT2A-MLLT3 leukemia cells were transduced with MSCVRXRA-IRES-mCherry or MSCV-RXRA DT448/9PP-IRES-mCherry
and treated with or without 250 nM bexarotene. After 24 h,
mCherry+ cells were sorted and total RNA was extracted with
TRIzol LS (Ambion Life Technologies) and isolated on PureLink
RNA Kit columns (Thermo Fisher Scientific). The quality of RNA
was measured on a 2100 Bioanalyzer (Agilent). Sequencing
libraries, each with individual Illumina indexes, were constructed
using the TruSeq Stranded mRNA procedure (Sample Prep Kit v2;
Illumina). Libraries were sequenced as paired-end 151 bp reads on
an Illumina NovaSeq instrument. Reads were aligned to the mm10
mouse reference genome, and transcription was quantified using
kallisto version 0.43.1 13 and Ensembl transcripts version 95. The R
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Results
Effects of RXRA DT448/9PP on maturation
We recently evaluated a series of RXRA truncations and
mutations to map the domains of RXRA required for antileukemic effects in murine KMT2A-MLLT3 (formerly MLLAF9) leukemia cells derived from Mx-Cre x Rxraflox/flox x
Rxrbflox/flox bone marrow cells (RXR-KO KMT2A-MLLT3
leukemia).5 Ghosh et al. had previously observed that RXRA
DT448/9PP was associated with increased binding to an
NCOR2 co-repressor (nuclear receptor corepressor 2, formerly SMRT) peptide in a GST pull-down assay.16 We
included this variant as part of the screen to evaluate corepressor requirements. DT448/9 is positioned at the end of
the turn between helix 11 and 12. Helix 11 directly binds to
co-repressors and co-activators.17 Helix 12 (the AF2 domain)
adopts an extended and unstructured conformation in the
absence of ligand and assumes a repositioned and helical
conformation following ligand binding (Figure 1A).18
Unexpectedly, retroviral expression of RXRA DT448/9PP
(MSCV-RXRA DT448/9PP-IRES-mCherry) in RXR-KO
KMT2A-MLLT3 leukemia cells induced the normally round
cells to form adherent clumps that were mCherry+ on the
tissue culture plate (Figure 1B). mCherry+ cells were also
associated with loss of leukemic colony-forming capacity,
lack of proliferation, and macrophage-like cytomorphology
with ruffled borders and vacuoles (Figure 1C-E). These
effects were absent in RXR-KO KMT2A-MLLT3 cells retrovirally transduced with RXRA WT (MSCV-RXRA-IRESmCherry), with other tested RXRA domain deletions or
point mutations, or with treatment combinations of RXRA
and RARA activating ligands5 (Figure 1B). In addition, we
found that retroviral expression of RXRA DT448/9PP
(MSCV-RXRA DT448/9PP-IRES-mCherry) in KMT2AMLLT3 WT leukemia cells induced the same phenotype as
that observed in RXR-KO KMT2A-MLLT3 leukemia cells
(lack of proliferation and macrophage-like cytomorphology) (data not shown). We examined the resulting proteins on
western blot after transduction into KMT2A-MLLT3 WT
cells (Figures 1F). RXRA DT448/99PP was associated with a
similar sized band as wild-type RXRA, but it appeared
resistant to the proteolytic cleavage that results in the formation of a truncated 36 kDa fragment.19 Endogenous Rxra
levels were significantly lower than levels of retrovirally
expressed RXRA (Figure 1G). Thus, retroviral transduction
led to similar levels of expression of RXRA WT and RXRA
DT448/9PP, at supraphysiological protein levels compared
to endogenous RXRA.
haematologica | 2022; 107(2)
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Figure 1. Monocytic maturation induced by RXRA DT448/9PP. (A) DT448/9 amino acids are highlighted in red within the structure of the RXRA ligand binding domain
(PDB 4K4J). An Ncoa2 peptide is highlighted in orange. Note that DT448/9 occurs at the beginning of helix 12, the AF2 domain, and the rigid proline substitution
could enhance helix formation. (B, C) RXR-KO KMT2A-MLLT3 leukemia cells were transduced with MSCV-RXRA DT448/9PP-IRES-mCherry or with MSCV-RXRA WTIRES-mCherry. Cells were evaluated under fluorescent and light microscopy at 72 h. (B) Transduced cells were sorted for mCherry+ cells and plated in methylcellulose,
and colonies assessed in technical triplicates on day 7. Statistical significance evaluated using the t-test, ***P<0.001 (C). (D) RXR-KO KMT2A-MLLT3 leukemia cells
were transduced with MSCV-RXRA DT448/9PP-IRES-mCherry, stained with FxCycle violet, and retention of the dye was assessed by flow cytometry at the indicated
time points comparing mCherry+ (RXRA DT 448/9 PP) versus mCherry– (RXR-KO) cells. (E) Cytomorphology of mCherry+ (RXRA DT 448/9 PP) versus mCherry– (RXRA
WT endogenous) sorted KMT2A-MLLT3 leukemia cells after transduction with MSCV-RXRA DT448/9PP-IRES-mCherry. (F) RXR-KO KMT2A-MLLT3 leukemia cells were
transduced with MSCV-RXRA DT448/9PP-IRES-mCherry or with MSCV-RXRA-IRES-mCherry and protein expression was evaluated through western blot analysis using
anti-RXRA antibody (H-10, Santa Cruz). GAPDH was used as a loading control. (G) KMT2A-MLLT3 WT leukemia cells were transduced with MSCV-RXRA WT-IRESmCherry as indicated, and protein expression was evaluated through western blot analysis using anti-RXRA antibody (5388, Cell Signaling). GAPDH was used as a
loading control. (H) KMT2A-MLLT3 WT leukemia cells were transduced as indicated and analyzed by flow cytometry. RXRA WT cells were analyzed with and without
treatment with 250 nM bexarotene for 24 h. RAW 264.7 cells were used as a positive staining control, but not included in the statistical comparisons. Statistical significance was evaluated using analysis of variance with the Tukey correction for multiple comparisons, *P<0.05. **P<0.01. ***P<0.001.

haematologica | 2022; 107(2)

419

O. di Martino et al.

Because the RXRA DT448/9PP-transduced cells acquired
cell adhesion properties and ruffled borders suggestive of
macrophage-like maturation, we assessed immunophenotypic changes. Bexarotene treatment of RXRA WT transduced cells resulted in an increased percentage of cells
expressing F4/80, CD11b, CD14, and CD64, as determined
by flow cytometry, and increased the median fluorescence
intensity (MFI) of F4/80, CD11b, CD14, CD64, Ly6c, and
Gr1, but had little effect on CD115 expression. RXRA
DT448/9PP transduction resulted in increased percentages
of cells expressing CD11b, CD14, and CD64, with
increased MFI of CD11b, CD14, CD64, Ly6c and Gr1, consistent with myeloid and monocytic maturation, but lacking the classical macrophage marker CD115 (Figure 1H,
Online Supplementary Figure S1).
Transduction of RXRA DT448/9PP, but not RXRA WT
into two KMT2A-MLLT3-associated human cells (THP1
and MonoMac-6) also resulted in adherence to plastic with
the development of podocytes and ruffled borders (Online
Supplementary Figure S2). These effects required 4 to 6 days
to emerge, whereas adhesion and cell clumping in murine
KMT2A-MLLT3 cells typically required only 3 or 4 days. In
contrast, Kit+ murine bone marrow cells cultured in stem
cell media (stem cell factor, interleukin 3, thrombopoietin,
Flt3L) and K562 cells were resistant to the effects of RXRA
DT448/9PP, and the cells remained round and non-adherent
(Online Supplementary Figures S2D and S3A, B).

RXRA DT448/9PP is constitutively active
We assessed the functional activity of RXRA DT448/9PP
using multiple reporter systems. First, we used a UAS/Gal4
reporter.11 KMT2A-MLLT3 WT leukemia cells derived from
UAS-GFP bone marrow cells were retrovirally transduced
with a fusion of the Gal4 DNA binding domain and the
RXRA wild-type ligand-binding domain (Gal4-RXRA) or a
fusion of the Gal4 DNA-binding domain and the RXRA
DT448/9PP
ligand-binding
domain
(Gal4-RXRA
DT448/9PP). Gal4-RXRA DT448/9PP resulted in constitutive activity uninfluenced by increasing concentrations of
bexarotene (Figure 2A). Constitutive activity of RXRA
DT449/8PP was also observed in Kit+ UAS-GFP bone marrow cells transduced with Gal4-RXRA retroviruses (Online
Supplementary Figure S3C).
Second, we evaluated three different luciferase reporters
in 293T cells. 293T cells are known to express endogenous
RXRA as well as various of its partners; RARA, PPARG, and
VDR.20 Reporters assays included a synthetic direct repeat 1
(DR1) peroxisome proliferator response element (PPRE); a
DR1 response element from the ApoA1 promoter; and a
DR5 response element from the RARB promoter. We noted
that RXRA DT448/9PP transfection consistently led to ligand-independent activation of all three constructs (Figure
2B). A control RXRA construct contained a deletion of the
AF2 domain (RXRA DAF2), and this construct is unresponsive to ligand. Using this approach we assessed whether
RXRA DT448/9PP might be sensitive to inhibition by two
pan-RXR antagonists, HX531 and UVI3003. Neither compound inhibited activation of the UAS/Gal4 reporter or the
RARE-Luc reporter (Figure 2C).
We used a mammalian two-hybrid assay to assess the
interaction of RXRA DT448/9PP with the co-activator
PGC1a, noting constitutive, ligand-independent binding
(Figure 2D, E). This activity remained present with the
L2/3A variant (L147A, L148A, L210A, L211A),21 which contains point mutations in the critical LXXLL motifs required
420

for ligand-dependent interactions of PGC1a with nuclear
receptors. Thus, RXRA DT448/9PP appears to constitutively engage PGC1a using domains outside the canonical Nterminal LXXLL motifs.

Comparison with other active RXRA variants
Two other RXRA variants with constitutively active properties have been described. First, mouse Rxra F318A exhibits
constitutively active phenotypes.22 However, when a crystal
structure was generated, the ligand-binding pocket contained oleic acid, and Rxra F318A activity could be inhibited
by the pan-RXR antagonist HX531, suggesting that the
mutation leads to augmented responsiveness to a natural ligand present in the tissue culture, and is not completely ligand-independent.23
We assessed the sensitivity of RXRA DT448/9PP to two
pan-RXR antagonists (HX531 and UVI3003) across a series
of assays. In RXR-WT KMT2A-MLLT3 leukemia cells transduced with RXRA DT448/9PP, cell adhesion, clumping, and
loss of proliferation phenotypes were not abrogated by
either compound (Online Supplementary Figure S4).
To further assess whether RXRA DT448/9PP phenotypes may result from hyper-responsiveness to intracellular natural ligands, we mutated two amino acids (R316
and L326) that form critical ionic bonds with the carboxylic acid group in ligands (e.g., bexarotene, 9-cis
retinoic acid, and long-chain fatty acids).5 RXRA
R316A/L326A has been previously shown to abrogate ligand-dependent activation and is unable to rescue response
to bexarotene in RXR-KO KMT2A-MLLT3 leukemia
cells.5,24 Retroviral expression of the compound variant
RXRA R316A/L326A/DT448/9PP again led to overexpression on western blot and resistance to proteolytic cleavage, but did not abrogate cell clumping, loss of proliferation, or loss of colony formation (Figure 3A-D).
Second, recurrent RXRA hot-spot mutations (S427F/Y)
occur in patients with bladder cancer, and these augment the
activity of the PPARG:RXRA heterodimer, but are not capable of independently activating RXRA reporters.25 Retroviral
expression of RXRA S427F also led to strong overexpression
of the variant, which retained sensitivity to proteolytic
cleavage, although cell adhesion, cell clumping, cell proliferation, and colony-forming properties were not altered
(Figure 3E-H).
To determine whether similar heterodimerization with
PPARG or with other nuclear receptors may play essential
roles in the activity of RXRA DT448/9PP, we evaluated phenotypes using a series of receptor antagonists. Concurrent
treatment with potent antagonists of retinoic acid receptors,
LXR, PPARA, and PPARG did not affect clumping, adhesion
to plastic, or proliferation phenotypes (Online Supplementary
Figure S5), demonstrating that the DT448/9PP creates a nonpermissive receptor that is functionally active, independently of other activated nuclear receptors.

RXRA DT448/9PP inhibits leukemic engraftment
and expansion
KMT2A-MLLT3 WT cells were transduced with RXRA
WT or RXRA DT448/9PP retroviruses labeled with IRESmCherry cassettes (Figure 4A). To limit maturation effects in
vitro, the populations were immediately transplanted into
recipient mice and residual cells were subsequently analyzed by flow cytometry. After 4 weeks of engraftment and
expansion, leukemia cells in the peripheral blood were
assessed and we observed that mice transplanted with
haematologica | 2022; 107(2)
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RXRA WT displayed increased leukocytosis, an increase in
neutrophils, and a decrease in lymphocytes compared to
mice transplanted with RXRA DT448/9PP-transduced cells
(Figure 4B-D). Compared with the pre-engraftment population (RXRA WT, 55% mCherry+; RXRA DT448/9PP, 62%
mCherry+), at 4 weeks there was reduced engraftment in
RXRA DT448/9PP cells relative to RXRA WT cells: RXRA
WT average of 7.6% mCherry+ cells (range, 0.94%-16.4%)
versus RXRA DT448/9PP 0.25% mCherry+ cells (range,

A

0.095%-0.36%) (Figure 4E). When we assessed moribund
mice transplanted with cells transduced with RXRA WT,
we observed further reduction in the absolute proportion of
mCherry+ cells in the bone marrow rather than an expansion: RXRA WT, average 1% (range, 1.21%-1.46%); RXRA
DT448/9PP, average 0.741 (range, 0.022%-1.46%) (Figure
4G). Survival was shorter in mice transplanted with RXRA
WT-transduced cells than in those transplanted with RXRA
DT448/9PP-transduced cells (Figure 4H). At the time of sac-

B

C

D

E

Figure 2. Constitutive activity of RXRA DT448/9PP. (A) KMT2A-MLLT3 WT leukemia cells derived from UAS-GFP bone marrow cells were transduced with MSCV-Gal4RXRA DT448/9PP-IRES-mCherry or MSCV-Gal4-RXRA-IRES-mCherry, treated with increasing concentrations of bexarotene, and the ratio of GFP+ cells (responding)
to total mCherry+ cells (capable of responding) was determined. Data from biological duplicates are shown. (B, C) 293T cells were transfected with the indicated plasmids, treated with bexarotene, HX531, or UVI3003 (all 1 mM), and luciferase was measured after 40 h. Data from biological triplicates are shown. PPRE: peroxisome
proliferator response element. ApoA1: DR1 element from the ApoA1 promoter. RARE: retinoic acid receptor response element from the RARB promoter. The ∆AF2
deletion acts as a negative control. (D, E) Mammalian two-hybrid. 293T cells were transfected with the indicated plasmids, treated with bexarotene and GFP was
measured by flow cytometry after 40 h. Data from biological triplicates are shown. GFP-N1: a positive control CMV-GFP expression vector. GFP-N0: a negative control
derived from GFP-N1 after the deletion of the CMV promoter. Statistical significance was evaluated using analysis of variance with the Bonferroni comparison to control, *P<0.05, **P<0.01, ***P<0.001.
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rifice, all but one mouse had developed splenomegaly (average spleen weight 0.5 g) and bone marrow lacked erythroid
elements, features that are typical of overwhelming secondary leukemic engraftment (Online Supplementary Figure S6).

Transcriptional consequences of RXRA DT448/9PP
To assess the maturation effects of RXRA DT448/9PP
more comprehensively and to investigate the overlapping

A

consequences with RXRA WT activation by bexarotene,
KMT2A-MLLT3 WT leukemia cells were transduced with
RXRA WT or RXRA DT448/9PP and the transcriptional profiles of the transduced cells were assessed by RNA sequencing (Figure 5A). We noted significant overlap of regulated
genes between RXRA WT cells treated with bexarotene and
cells transduced with RXRA DT448/9PP (Figure 5B-D). Of
598 genes that were upregulated in RXRA WT cells treated

B
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H

Figure 3. Comparison with other RXRA variants with activity. KMT2A-MLLT3 WT leukemia cells were transduced with MSCV-3xFlag-RXRA R316A/L326A/DT448/9PPIRES-mCherry or with MSCV-RXRA S427F-IRES-mCherry and evaluated under fluorescent and light microscopy at 72 h (A and E). RXR-KO KMT2A-MLLT3 leukemia
cells were transduced with MSCV-3xFlag-RXRA R316A/L326A/DT448/9PP-IRES-mCherry or MSCV-RXRA S427F-IRES-mCherry, stained with FxCycle Violet, and
retention of the dye was assessed by flow cytometry at the indicated time points (B and F). RXR-KO KMT2A-MLLT3 leukemia cells were transduced with MSCV-RXRA
WT-IRES-mCherry or MSCV-3xFlag-RXRA R316A/L326A/DT448/9PP-IRES-mCherry or MSCV-RXRA S427F-IRES-mCherry, mCherry+ cells were then sorted and plated
in methylcellulose, and colonies assessed in technical triplicates on day 7 (C and G). RXR-KO KMT2A-MLLT3 leukemia cells were transduced with MSCV-RXRA-IRESmCherry or MSCV-RXRA DT448/9PP-IRES-mCherry or MSCV-RXRA S427F-IRES-mCherry and protein expression was evaluated through western blot analysis using
anti-RXRA antibody (H-10, Santa Cruz). GAPDH was used as a loading control (D and H). Statistical significance was evaluated using the t-test, ***P<0.001.
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with bexarotene, 525 overlapped with those of RXRA
DT448/9PP-transduced cells. Likewise, of 74 downregulated
genes in RXRA WT cells treated with bexarotene, 28 overlapped with those in RXRA DT448/9PP-transduced cells.
Gene ontology pathway analysis showed enrichment of
lipid metabolism and immune system signaling and downregulation of RNA processing (Online Supplementary Tables
S1 and S2). Gene set enrichment analysis of a curated list of
genes regulated during myeloid development26 indicated
that treatment of RXRA WT cells with bexarotene and
expression of RXRA DT448/9PP both lead to a myeloid differentiation phenotype (upregulation of “Up” genes and

downregulation of “Down” genes) compared to untreated
WT cells (Figure 5E, F).
Within this set of differentially expressed genes, we evaluated transcripts associated with cell surface proteins.
Sixty-seven cell surface transcripts were differentially
expressed, according to RNA sequencing, between RXRA
WT cells versus RXRA WT cells treated with bexarotene or
RXRA DT448/9PP-transduced cells (Online Supplementary
Figure S7A). As in the overall RNA sequencing analysis,
these genes were associated with similar or greater upregulation in DT448/9PP-transduced cells than in the wild-type
cells treated with bexarotene (Online Supplementary Figure
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Figure 4. In vivo engraftment with RXRA WT cells
versus RXRA DT448/9PP-transduced cells. (A)
Experimental schema. KMT2A-MLLT3 WT
leukemia cells were transduced with MSCV-RXRA
WT-IRES-mCherry or MSCV-RXRA DT448/9PPIRES-mCherry and transplanted immediately into
sublethally irradiated mice. (B-D) Peripheral blood
assessment at 4 weeks. WBC: white blood cells.
(E) Assessment of proportion of mCherry+ cells
before transplantation. (F) Assessment of mCherry
in peripheral blood at 4 weeks. (G) Assessment of
mCherry in bone marrow of moribund mice (of
note, 2 RXRA DT448/9PP mice were found dead
and were unable to be assessed and 1 was sacrificed but did not have splenomegaly). (H) Survival
of mice after transplantation. *P<0.05,
**P<0.01. The Mann-Whitney test was used in (B,
F and G) with unequal variance. Otherwise, the ttest was used.
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S7B-F). The list of upregulated genes included CD14 and
CD64 (Fcgr1), which at the protein level were observed to
increase by immunofluorescence (Figure 1H, Online
Supplementary Figure S1C-D). The most highly differentiated transcript out of the cell surface markers was the complement factor C3 (Online Supplementary Figure S7D), and
additional complement-receptors (C5ar1 and CD59a) also
underwent upregulation with RXRA activation (Online
Supplementary Figure S7B, F), which correlate with monocytic differentiation. We also noted a variety of upregulated
integrins (Bcam, Ceacam1, Itgam, Itgb2, Itgb2l, and Itgb7),
and these may play a role in the aggregation phenotype of
the DT448/9PP variant (Online Supplementary Figure S7C-F).
While the majority of transcripts that were up- or downregulated overlapped between RXRA WT cells treated with

bexarotene and RXRA DT448/9PP-transduced cells (Figure
5B-D), there were 11 genes that were differentially
expressed between these two groups (Online Supplementary
Figure S8A). In five, RXRA DT448/9PP augmented the
bexarotene-induced response: (upregulated Vsig8, Fcgr1
(Cd64), Camp, Gp6; downregulated: Pik3ip1) (Online
Supplementary Figure S8B). The other six displayed three different patterns: not expressed in treated or untreated RXRA
WT cells and increased in DT448/9PP-transduced cells
(Gpr84, S100a8); downregulated from untreated to treated
RXRA WT cells and expressed in DT448/9PP-transduced
cells (Mpo, Gm28438, Gm10359); or not expressed in
untreated RXRA WT with an increase upon bexarotene
treatment but not with DT448/9PP (Cited1) (Online
Supplementary Figure S8C). This list is too small for pathway
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C

E

B

D

F

Figure 5. RXRA DT448/9PP transcriptome changes. (A) Schema of experimental design: KMT2A-MLLT3 WT leukemia cells were transduced with the indicated viruses and cultured for 24 h with or without 250 nM bexarotene; mCherry+ cells were sorted, and total RNA was isolated for RNA sequencing analysis. (B) Heatmap of
differentially expressed genes (DEG) between all three groups. Each condition was evaluated by biological triplicates. WT: RXRA WT cells; WT + bex: RXRA WT cells
treated with bexarotene; DT448/9PP: RXRA DT448/9PP-transduced cells. (C) Venn diagram with the number of upregulated unique DEG from RXRA WT cells versus
RXRA WT cells treated with bexarotene (red) and RXRA WT cells versus RXRA DT448/9PP-transduced cells (blue) and DEG common to both groups (purple). (D) Venn
diagram with the number of downregulated unique DEG from RXRA WT cells versus. RXRA WT cells treated with bexarotene (red) and RXRA WT cells versus RXRA
DT448/9PP-transduced cells (blue) and DEG in common between both groups (purple). (E, F) Gene set enrichment analysis comparing the untreated RXRA WT cells
to the bexarotene-treated and DT448/9PP-transduced cells upregulated (E) and downregulated (F) during myelopoiesis (published gene sets from Brown, et al.26).
Heatmaps are shown as row z-scores with the color key below the panel (B). FDR: false discovery rate; NES: normalized enrichment score.
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analysis, but manual curation found that the most of these
11 transcripts are related to immune function and activity.

Discussion
Retinoic X receptors and retinoic acid receptors have
been shown to influence myeloid maturation.1,2,4,27,28 RXRA
protein levels and activity have been linked to cell fate decisions at the neutrophil versus monocyte decision,29 and deletion of Rxra and Rxrb prevents osteoclast maturation.12 and
augments KMT2A-MLLT3 leukemogenesis and cell expansion in vivo,5 suggesting a role for retinoic X receptors in regulating myeloid maturation.
RXRA DT448/9PP is a serendipitously discovered mutation that results in constitutive activity, leukemic cell maturation, and loss of proliferative capacity. This variant
demonstrates ligand-independent activation, augmented
co-activator binding, induced maturation transcripts by
RNA sequencing, and reduced engraftment in vivo. To our
knowledge, RXRA DT448/9PP has not been spontaneously
observed in cancer or other pathological states.
Two other RXRA mutations with activating phenotypes
have been described. Mouse Rxra F318A has increased transcriptional activity, potentially via increased responsiveness
to cell-available oleic acid.22 However, Rxra F318A retains
sensitivity to RXRA antagonists, whereas RXRA
DT448/9PP did not (Figure 2C, Online Supplementary Figure
S2). Furthermore, R316 and L326 are critical amino acids
that interact directly with bound ligand and are required for
ligand activation of RXRA.5,24 Combining these ligandblocking mutations with DT448/9PP, we noted retained
KMT2A-MLLT3 maturation phenotypes (Figure 3A-C), further suggesting ligand-independent activity of RXRA
DT448/9PP. Recurrent RXRA hot-spot mutations (S427F/Y)
have been noted in patients with bladder cancer. These
mutations augment the activity of the PPARG:RXRA heterodimer and are not capable of independently activating
RXRA in reporter assays.25 We previously found that combinations of RARA and RXRA ligands lead to leukemic
maturation and apoptosis, whereas PPARG and RXRA ligands did not.5 Here we found that RXRA S427F did not
recapitulate leukemia maturation phenotypes in KMT2AMLLT3 leukemia cells (Figure 3E-G), and the PPARG antagonist T0070907 did not abrogate RXRA DT448/9PP phenotypes (Online Supplementary Figure S5). Thus, in contrast to
Rxra F318A and RXRXA S427F, RXRA DT448/9PP may be
constitutively active, independently of endogenous, available, natural ligands, and also may not depend on activation
through PPARG:RXR heterodimers or other major nuclear
receptor heterodimers.
RXRA DT448/9PP constitutive activity may be related to
at least two phenotypes. RXRA DT448/9PP is resistant to
enzymatic cleavage, and this may enable augmented functional protein levels (Figures 1F and 3D, H), but cannot
explain resistance to pan-RXR antagonists or co-mutation
with R316A/L326A (Figures 2C and 3A-C, Online
Supplementary Figure S4). RXRA DT448/9PP was also associated with ligand-independent co-activator binding (Figure
2D), which may enable augmented, or even constitutive
activity. A limitation of these studies is that they require a
retroviral overexpression system and therefore the effect of
DT448/9PP RXRA at physiological levels is unknown.
Not all cells tested were susceptible to RXRA DT448/9PP.
The two human myelomonocytic acute myeloid leukemia
haematologica | 2022; 107(2)

lines with KMT2A-MLLT3 (THP1 and MonoMac-6) were
susceptible, whereas the heterogeneous stem/progenitor
populations of Kit+ murine bone marrow cells and the blast
phase chronic myeloid leukemia cell line K562 were not
(Online Supplementary Figures S2 and S3). Maintained in
stem cell cytokines, Kit+ bone marrow cells have multipotent potential and their medium lacks cytokines that might
provide monocytic maturation support. K562 cells are susceptible to erythroid maturation stimuli rather than
myeloid maturation. Other groups have observed differences in sensitivity and resistance to retinoids across cell
lines.9,30,31 Thus, different external signals and/or internal
priming states may affect the susceptibility to retinoids and
to RXRA DT448/9PP.
We have previously noted that Rxra and Rxrb expression
negatively regulates KMT2A-MLLT3 leukemia and that
these cells are exposed to low levels of natural RXRA ligands in vivo.5,32 Similarly, here we found that cells that overexpress RXRA WT consistently engraft in recipient mice,
but are associated with a competitive disadvantage relative
to untransduced, mCherry-negative cells (Figure 4). This
phenotype was augmented by transduction with RXRA
DT448/9PP, which further limited engraftment and
leukemic outgrowth in vivo, again suggesting the potential
of activated retinoic X receptors to inhibit growth of
leukemia cells in vivo.
RXRA DT448/9PP resulted in several maturation-related
phenotypes, including lack of proliferation, loss of colony
formation, acquisition of ruffled borders and podocytes,
and increased expression of cell surface markers of myeloid
and monocytic maturation. Transcriptional analysis of
bexarotene-treated cells versus RXRA DT448/9PP-transduced cells suggested strong overlapping myeloid and
monocytic maturation signatures, consistent with ligandindependent, constitutively active effects of DT448/9PP.
Many maturation-related transcripts were more effectively
induced by RXRA DT448/9PP than by bexarotene, and a
few myeloid-related transcripts were uniquely induced by
RXRA DT448/9PP. Thus, DT448/9PP may more effectively
activate the same loci as ligand-activated RXRA, and activity at select novel loci may enable additional phenotypes.
Like other nuclear receptors, the retinoic X receptors are
ligand-dependent transcription factors and their function
and activity change from transcriptional repressors to transcriptional activators in the presence of active ligands.
Multiple natural ligands have been proposed for the retinoic
X receptors,6 and it is often difficult to know which cells
and settings contain active, natural ligands, and when an
observed effect of retinoic X receptors may be related to the
receptor function in the absence versus presence of ligand. A
constitutively active variant provides a helpful genetic comparator and could be used with diverse forms of previously
characterized non-functional (e.g., DDBD, E153G/G154S)
and ligand-non-responsive variants (e.g., DAF2,
R316A/326A).
Retinoid receptors have been an attractive therapeutic
target in acute myeloid leukemia; however their effects in
clinical trials have been modest. The maturation effects
(loss of proliferation and colony-forming potential, and
morphological changes) of DT448/9PP on KMT2A-MLLT3
leukemia cells are more robust than the maximal effects of
retinoid ligands such as all-trans retinoic acid and
bexarotene. Although further delineation of mechanistic
activity and cell-type susceptibility rules will be required,
these data suggest that current small-molecule retinoids
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O. di Martino et al.

may incompletely activate the maturation pathways regulated by the retinoid receptors and that additional, unrealized potential may exist for retinoids in the treatment of
forms of acute myeloid leukemia other than non-acute
promyelocytic leukemia. In particular, myeloid maturation
programs may be augmented by correctly activated retinoic
X receptors and cells with monocytic potential may be susceptible to retinoid-induced maturation. An efficient, constitutively active RXRA variant may enable further elucidation of this potential.
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